Circio Holding ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates

Oslo, 24 June 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (the "Company") earlier today, 24 June 2024, regarding the commencement of the subscription period for the rights issue (the "Rights Issue"). As part of this process, subscription rights have been allocated to primary insiders and their close associates. Please see the attached notifications of trade for information regarding the subscription rights received by primary insiders and their close associates in the Rights Issue. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, CFO Phone: +34 683343811 Email: lubor.gaal@circio.com About Circio Building next generation RNA therapeutics Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines. Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold -standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden. In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.